{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:24:47Z","timestamp":1794288287111,"version":"4.9.0"},"reference-count":183,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Meningiomas are the most common primary intracranial neoplasm with diverse pathological types and complicated clinical manifestations. The fifth edition of the WHO Classification of Tumors of the Central Nervous System (WHO CNS5), published in 2021, introduces major changes that advance the role of molecular diagnostics in meningiomas. To follow the revision of WHO CNS5, this expert consensus statement was formed jointly by the Group of Neuro-Oncology, Society of Neurosurgery, Chinese Medical Association together with neuropathologists and evidence-based experts. The consensus provides reference points to integrate key biomarkers into stratification and clinical decision making for meningioma patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration:<\/jats:title>\n                    <jats:p>Practice guideline REgistration for transPAREncy (PREPARE), IPGRP-2022CN234<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000002391","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T16:00:10Z","timestamp":1664553610000},"page":"1894-1912","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Molecular diagnosis and treatment of meningiomas: an expert consensus (2022)"],"prefix":"10.1097","volume":"135","author":[{"given":"Jiaojiao","family":"Deng","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China"},{"name":"National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyang","family":"Hua","sequence":"additional","affiliation":[{"name":"Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai 200040, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai 200040, China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery, Shanghai 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuguan","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Huashan Hospital, Fudan University, Shanghai 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changwu","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 750306, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dangmurenjiapu","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Shanxi Medical University Shanxi Provincial People's Hospital, Taiyuan, Shanxi 030012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugang","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Soochow, Jiangsu 215004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, Shandong 250063, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songtao","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi\u2019an, Shaanxi 710038, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songsheng","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fujian Medical University Affiliated Union Hospital, Fuzhou, Fujian 350001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochuan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong 510080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"You","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kunming Medical University First Affiliated Hospital, Kunming, Yunnan 650032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyuan","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin 300052, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhong","sequence":"additional","affiliation":[{"name":"Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai 200040, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai 200040, China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery, Shanghai 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China"},{"name":"National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Group of Neuro-Oncology, Society of Neurosurgery, Chinese Medical Association","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,20]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"iii1\u2013iii105","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018","volume":"23","author":"Ostrom","year":"2021","journal-title":"Neuro Oncol"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","article-title":"A clinically applicable integrative molecular classification of meningiomas","volume":"597","author":"Nassiri","year":"2021","journal-title":"Nature"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.21.00784","article-title":"Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated","volume":"39","author":"Maas","year":"2021","journal-title":"J Clin Oncol"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1750-3639.1993.tb00752.x","article-title":"The new WHO classification of brain tumours","volume":"3","author":"Kleihues","year":"1993","journal-title":"Brain Pathol"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro Oncol"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science"},{"key":"R13-20250603","first-page":"1","article-title":"Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas","author":"Youngblood","year":"2019","journal-title":"J Neurosurg"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"21715","DOI":"10.1073\/pnas.1912858116","article-title":"Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors","volume":"116","author":"Patel","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/neuonc\/noab213","article-title":"A molecularly integrated grade for meningioma","volume":"24","author":"Driver","year":"2022","journal-title":"Neuro Oncol"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO.20.03237","article-title":"Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline","volume":"39","author":"Chen","year":"2021","journal-title":"J Clin Oncol"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1073\/pnas.84.15.5419","article-title":"Molecular genetic approach to human meningioma: loss of genes on chromosome 22","volume":"84","author":"Seizinger","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40478-022-01362-3","article-title":"Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management","volume":"10","author":"Daoud","year":"2022","journal-title":"Acta Neuropathol Commun"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1038\/s41598-021-86298-9","article-title":"Associations of pathological diagnosis and genetic abnormalities in meningiomas with the embryological origins of the meninges","volume":"11","author":"Okano","year":"2021","journal-title":"Sci Rep"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0294-180","article-title":"Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas","volume":"6","author":"Ruttledge","year":"1994","journal-title":"Nat Genet"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/neuonc\/noy178","article-title":"Molecular and translational advances in meningiomas","volume":"21","author":"Suppiah","year":"2019","journal-title":"Neuro Oncol"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41525-017-0014-7","article-title":"Genomic landscape of high-grade meningiomas","volume":"2","author":"Bi","year":"2017","journal-title":"NPJ Genom Med"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1215\/S1152851704000158","article-title":"Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas","volume":"6","author":"Pfisterer","year":"2004","journal-title":"Neuro Oncol"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/neup.12266","article-title":"Activation of multiple growth factor signalling pathways is frequent in meningiomas","volume":"36","author":"Hilton","year":"2016","journal-title":"Neuropathology"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"737523","DOI":"10.3389\/fonc.2021.737523","article-title":"Case report: identification of a novel GNAS mutation and 1p\/22q co-deletion in a patient with multiple recurrent meningiomas sensitive to sunitinib","volume":"11","author":"Hong","year":"2021","journal-title":"Front Oncol"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/S0140-6736(09)60259-2","article-title":"Neurofibromatosis type 2","volume":"373","author":"Asthagiri","year":"2009","journal-title":"Lancet"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnen\/60.6.628","article-title":"Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications","volume":"60","author":"Cai","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4103\/0377-4929.168852","article-title":"1p\/14q co-deletion: a determinant of recurrence in histologically benign meningiomas","volume":"58","author":"Kakkar","year":"2015","journal-title":"Indian J Pathol Microbiol"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"e94987","DOI":"10.1371\/journal.pone.0094987","article-title":"Molecular biological determinations of meningioma progression and recurrence","volume":"9","author":"Linsler","year":"2014","journal-title":"PLoS One"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2176\/nmc.50.27","article-title":"Fluorescent in situ hybridization 1p\/19q deletion\/imbalance analysis of low-grade and atypical meningiomas","volume":"50","author":"Nagasaka","year":"2010","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"R33-20250603","first-page":"226","article-title":"Cytogenetic alterations in meningioma tumors and their impact on disease outcome (in Spanish)","volume":"128","author":"Sayagu\u00e9s","year":"2007","journal-title":"Med Clin (Barc)"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.pjnns.2016.08.003","article-title":"Recurrence-associated chromosomal anomalies in meningiomas: single-institution study and a systematic review with meta-analysis","volume":"50","author":"Och","year":"2016","journal-title":"Neurol Neurochir Pol"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0165-4608(98)00209-X","article-title":"Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas","volume":"110","author":"Lamszus","year":"1999","journal-title":"Cancer Genet Cytogenet"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1227\/01.NEU.0000290895.92695.22","article-title":"De novo versus transformed atypical and anaplastic meningiomas: comparisons of clinical course, cytogenetics, cytokinetics, and outcome","volume":"61","author":"Krayenb\u00fchl","year":"2007","journal-title":"Neurosurgery"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1158\/0008-5472.CAN-05-0043","article-title":"Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma","volume":"65","author":"Lusis","year":"2005","journal-title":"Cancer Res"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijrobp.2019.11.028","article-title":"High-risk Meningioma: Initial Outcomes From NRG Oncology\/RTOG 0539","volume":"106","author":"Rogers","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"311","DOI":"10.5414\/NP300580","article-title":"Genetic changes with prognostic value in histologically benign meningiomas","volume":"32","author":"Barbera","year":"2013","journal-title":"Clin Neuropathol"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1227\/01.neu.0000303201.62123.5c","article-title":"Fluorescent in situ hybridization and ex vivo 1H magnetic resonance spectroscopic examinations of meningioma tumor tissue: is it possible to identify a clinically-aggressive subset of benign meningiomas?","volume":"61","author":"Pfisterer","year":"2007","journal-title":"Neurosurgery"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0165-4608(03)00279-6","article-title":"Association of loss of 1p and alterations of chromosome 14 in meningioma progression","volume":"148","author":"Lopez-Gines","year":"2004","journal-title":"Cancer Genet Cytogenet"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-012-1038-6","article-title":"MEG3: a novel long noncoding potentially tumour-suppressing RNA in meningiomas","volume":"112","author":"Balik","year":"2013","journal-title":"J Neurooncol"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.4103\/0028-3886.193768","article-title":"Fluorescence in situ hybridization for chromosome 14q deletion in subsets of meningioma segregated by MIB-1 labelling index","volume":"64","author":"Gupta","year":"2016","journal-title":"Neurol India"},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00401-017-1678-x","article-title":"Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma","volume":"133","author":"Olar","year":"2017","journal-title":"Acta Neuropathol"},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"14719","DOI":"10.1073\/pnas.94.26.14719","article-title":"Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression","volume":"94","author":"Weber","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/cancers13040903","article-title":"Molecular profiling of 22 primary atypical meningiomas shows the prognostic significance of 18q heterozygous loss and CDKN2A\/B homozygous deletion on recurrence-free survival","volume":"13","author":"Barresi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat Genet"},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/ng.3651","article-title":"Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas","volume":"48","author":"Clark","year":"2016","journal-title":"Nat Genet"},{"key":"R49-20250603","first-page":"827","article-title":"Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma","volume":"146","author":"Wellenreuther","year":"1995","journal-title":"Am J Pathol"},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/modpathol.2016.81","article-title":"Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system","volume":"29","author":"Yuzawa","year":"2016","journal-title":"Mod Pathol"},{"key":"R51-20250603","first-page":"1","article-title":"Clinical and genomic factors associated with seizures in meningiomas","author":"Gupte","year":"2020","journal-title":"J Neurosurg"},{"key":"R52-20250603","first-page":"vdz55","article-title":"The CREB-binding protein inhibitor ICG-001: a promising therapeutic strategy in sporadic meningioma with NF2 mutations","volume":"2","author":"Deng","year":"2020","journal-title":"Neurooncol Adv"},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/neuonc\/noaa226","article-title":"Associations of meningioma molecular subgroup and tumor recurrence","volume":"23","author":"Youngblood","year":"2021","journal-title":"Neuro Oncol"},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1128\/MCB.01578-08","article-title":"Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling","volume":"29","author":"L\u00f3pez-Lago","year":"2009","journal-title":"Mol Cell Biol"},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1128\/MCB.01581-08","article-title":"NF2\/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth","volume":"29","author":"James","year":"2009","journal-title":"Mol Cell Biol"},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s40478-020-01040-2","article-title":"Distinct genomic subclasses of high-grade\/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic","volume":"8","author":"Williams","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1038\/onc.2012.436","article-title":"Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation","volume":"32","author":"Peyre","year":"2013","journal-title":"Oncogene"},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/1078-0432.CCR-12-1904","article-title":"mTORC1 inhibitors suppress meningioma growth in mouse models","volume":"19","author":"Pachow","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11060-016-2172-3","article-title":"A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma","volume":"129","author":"Shih","year":"2016","journal-title":"J Neurooncol"},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","article-title":"Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial","volume":"26","author":"Graillon","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"e0217340","DOI":"10.1371\/journal.pone.0217340","article-title":"Systemic management of malignant meningiomas: a comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib","volume":"14","author":"Cardona","year":"2019","journal-title":"PLoS One"},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1158\/1535-7163.MCT-21-0143","article-title":"Phase 0 clinical trial of everolimus in patients with vestibular schwannoma or meningioma","volume":"20","author":"Karajannis","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1200\/JCO.2020.38.15_suppl.2502","article-title":"Alliance A071401: phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations","volume":"38","author":"Brastianos","year":"2020","journal-title":"J Clin Oncol"},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1200\/JCO.2003.07.156","article-title":"New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology","volume":"21","author":"Maillo","year":"2003","journal-title":"J Clin Oncol"},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00401-013-1195-5","article-title":"Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system","volume":"126","author":"Koelsche","year":"2013","journal-title":"Acta Neuropathol"},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00401-013-1198-2","article-title":"TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma","volume":"126","author":"Remke","year":"2013","journal-title":"Acta Neuropathol"},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas","volume":"372","author":"Brat","year":"2015","journal-title":"N Engl J Med"},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"101562","DOI":"10.1016\/j.canep.2019.07.001","article-title":"Incidence, mortality and outcome of meningiomas: a population-based study from Germany","volume":"62","author":"Holleczek","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"djv377","DOI":"10.1093\/jnci\/djv377","article-title":"TERT promoter mutations and risk of recurrence in meningioma","volume":"108","author":"Sahm","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/bpa.12110","article-title":"High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression","volume":"24","author":"Goutagny","year":"2014","journal-title":"Brain Pathol"},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/jnnp-2019-322257","article-title":"Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis","volume":"91","author":"Mirian","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11060-018-2912-7","article-title":"TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas","volume":"139","author":"Biczok","year":"2018","journal-title":"J Neurooncol"},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"747592","DOI":"10.3389\/fonc.2021.747592","article-title":"TERT alterations predict tumor progression in de novo high-grade meningiomas following adjuvant radiotherapy","volume":"11","author":"Deng","year":"2021","journal-title":"Front Oncol"},{"key":"R75-20250603","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1038\/s41467-021-25708-y","article-title":"Radiation-induced gliomas represent H3-\/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A\/B","volume":"12","author":"Deng","year":"2021","journal-title":"Nat Commun"},{"key":"R76-20250603","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11060-019-03333-6","article-title":"Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma","volume":"145","author":"Guyot","year":"2019","journal-title":"J Neurooncol"},{"key":"R77-20250603","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","article-title":"CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas","volume":"140","author":"Sievers","year":"2020","journal-title":"Acta Neuropathol"},{"key":"R78-20250603","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"R79-20250603","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10014-016-0271-7","article-title":"Genetic landscape of meningioma","volume":"33","author":"Yuzawa","year":"2016","journal-title":"Brain Tumor Pathol"},{"key":"R80-20250603","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s40478-019-0793-4","article-title":"Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT","volume":"7","author":"Jungwirth","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"R81-20250603","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4132\/jptm.2019.11.05","article-title":"Molecular characteristics of meningiomas","volume":"54","author":"Lee","year":"2020","journal-title":"J Pathol Transl Med"},{"key":"R82-20250603","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1055\/s-0038-1676821","article-title":"Genomic analysis of posterior fossa meningioma demonstrates frequent AKT1 E17K mutations in foramen magnum meningiomas","volume":"80","author":"Williams","year":"2019","journal-title":"J Neurol Surg B Skull Base"},{"key":"R83-20250603","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00401-013-1187-5","article-title":"AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry","volume":"126","author":"Sahm","year":"2013","journal-title":"Acta Neuropathol"},{"key":"R84-20250603","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.3171\/2018.2.FOCUS1849","article-title":"Clinical potential of meningioma genomic insights: a practical review for neurosurgeons","volume":"44","author":"Karsy","year":"2018","journal-title":"Neurosurg Focus"},{"key":"R85-20250603","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1038\/onc.2008.170","article-title":"AKT1(E17K) in human solid tumours","volume":"27","author":"Bleeker","year":"2008","journal-title":"Oncogene"},{"key":"R86-20250603","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/neuonc\/nov316","article-title":"Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma","volume":"18","author":"Abedalthagafi","year":"2016","journal-title":"Neuro Oncol"},{"key":"R87-20250603","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.18632\/oncotarget.27178","article-title":"New insights into the genomic landscape of meningiomas identified FGFR3 in a subset of patients with favorable prognoses","volume":"10","author":"AlSahlawi","year":"2019","journal-title":"Oncotarget"},{"key":"R88-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djw320","article-title":"Durable control of metastatic AKT1-mutant WHO Grade 1 meningothelial meningioma by the AKT inhibitor, AZD5363","volume":"109","author":"Weller","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"R89-20250603","doi-asserted-by":"crossref","first-page":"e12780","DOI":"10.1111\/nan.12780","article-title":"AKT1 -mutated meningioma cell lines respond to treatment with the AKT inhibitor AZD5363","volume":"48","author":"John","year":"2022","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R90-20250603","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1158\/0008-5472.CAN-20-3669","article-title":"Loss-of-function mutations in TRAF7 and KLF4 cooperatively activate RAS-Like GTPase signaling and promote meningioma development","volume":"81","author":"Najm","year":"2021","journal-title":"Cancer Res"},{"key":"R91-20250603","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.3171\/2017.12.FOCUS17756","article-title":"High-grade meningiomas: biology and implications","volume":"44","author":"Bi","year":"2018","journal-title":"Neurosurg Focus"},{"key":"R92-20250603","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/neuros\/nyab001","article-title":"Meningioma: a pathology perspective","volume":"89","author":"Toland","year":"2021","journal-title":"Neurosurgery"},{"key":"R93-20250603","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/neuonc\/nov177","article-title":"A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma","volume":"18","author":"Aizer","year":"2016","journal-title":"Neuro Oncol"},{"key":"R94-20250603","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00401-013-1093-x","article-title":"Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations","volume":"125","author":"Reuss","year":"2013","journal-title":"Acta Neuropathol"},{"key":"R95-20250603","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/S1470-2045(16)30321-7","article-title":"EANO guidelines for the diagnosis and treatment of meningiomas","volume":"17","author":"Goldbrunner","year":"2016","journal-title":"Lancet Oncol"},{"key":"R96-20250603","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","article-title":"The SWI\/SNF complex in cancer - biology, biomarkers and therapy","volume":"17","author":"Mittal","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"R97-20250603","doi-asserted-by":"crossref","first-page":"13537","DOI":"10.1038\/s41598-018-31659-0","article-title":"An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures","volume":"8","author":"Collord","year":"2018","journal-title":"Sci Rep"},{"key":"R98-20250603","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ng.2552","article-title":"Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas","volume":"45","author":"Smith","year":"2013","journal-title":"Nat Genet"},{"key":"R99-20250603","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00401-020-02247-2","article-title":"Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1","volume":"141","author":"Sievers","year":"2021","journal-title":"Acta Neuropathol"},{"key":"R100-20250603","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/path.4427","article-title":"Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas","volume":"234","author":"Smith","year":"2014","journal-title":"J Pathol"},{"key":"R101-20250603","doi-asserted-by":"crossref","first-page":"E396","DOI":"10.1093\/neuros\/nyz135","article-title":"Letter: familial syndromes involving meningiomas provide mechanistic insight into sporadic disease","volume":"85","author":"Lu","year":"2019","journal-title":"Neurosurgery"},{"key":"R102-20250603","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","article-title":"Biological mechanisms and clinical significance of BAP1 mutations in human cancer","volume":"10","author":"Carbone","year":"2020","journal-title":"Cancer Discov"},{"key":"R103-20250603","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/neuonc\/nox094","article-title":"Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas","volume":"19","author":"Shankar","year":"2017","journal-title":"Neuro Oncol"},{"key":"R104-20250603","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3390\/cancers11081114","article-title":"Families with BAP1-tumor predisposition syndrome in the netherlands: path to identification and a proposal for genetic screening guidelines","volume":"11","author":"Chau","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R105-20250603","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/neuonc\/nox094","article-title":"BAP1 mutations in high-grade meningioma: implications for patient care","volume":"19","author":"Shankar","year":"2017","journal-title":"Neuro Oncol"},{"key":"R106-20250603","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/322073a0","article-title":"Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy","volume":"322","author":"Kunkel","year":"1986","journal-title":"Nature"},{"key":"R107-20250603","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1158\/1078-0432.CCR-17-1856","article-title":"In-depth genetic analysis of sclerosing epithelioid fibrosarcoma reveals recurrent genomic alterations and potential treatment targets","volume":"23","author":"Arbajian","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R108-20250603","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/s41467-017-01355-0","article-title":"Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors","volume":"8","author":"Cheng","year":"2017","journal-title":"Nat Commun"},{"key":"R109-20250603","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4161\/cc.6.2.3733","article-title":"Digital karyotyping reveals frequent inactivation of the dystrophin\/DMD gene in malignant melanoma","volume":"6","author":"K\u00f6rner","year":"2007","journal-title":"Cell Cycle"},{"key":"R110-20250603","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ng.2974","article-title":"Dystrophin is a tumor suppressor in human cancers with myogenic programs","volume":"46","author":"Wang","year":"2014","journal-title":"Nat Genet"},{"key":"R111-20250603","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00401-018-1899-7","article-title":"DMD genomic deletions characterize a subset of progressive\/higher-grade meningiomas with poor outcome","volume":"136","author":"Juratli","year":"2018","journal-title":"Acta Neuropathol"},{"key":"R112-20250603","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00401-019-02008-w","article-title":"Mutational patterns and regulatory networks in epigenetic subgroups of meningioma","volume":"138","author":"Paramasivam","year":"2019","journal-title":"Acta Neuropathol"},{"key":"R113-20250603","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1158\/0008-5472.CAN-21-0628","article-title":"PBRM1 deficiency confers synthetic lethality to DNA repair inhibitors in cancer","volume":"81","author":"Chabanon","year":"2021","journal-title":"Cancer Res"},{"key":"R114-20250603","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-pathol-012414-040445","article-title":"SWI\/SNF chromatin remodeling and human malignancies","volume":"10","author":"Masliah-Planchon","year":"2015","journal-title":"Annu Rev Pathol"},{"key":"R115-20250603","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature09639","article-title":"Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma","volume":"469","author":"Varela","year":"2011","journal-title":"Nature"},{"key":"R116-20250603","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00401-020-02161-7","article-title":"Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features","volume":"140","author":"Williams","year":"2020","journal-title":"Acta Neuropathol"},{"key":"R117-20250603","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1038\/s41467-020-20242-9","article-title":"PRC2 and EHMT1 regulate H3K27me2 and H3K27me3 establishment across the zygote genome","volume":"11","author":"Meng","year":"2020","journal-title":"Nat Commun"},{"key":"R118-20250603","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nature23262","article-title":"Maternal H3K27me3 controls DNA methylation-independent imprinting","volume":"547","author":"Inoue","year":"2017","journal-title":"Nature"},{"key":"R119-20250603","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ccell.2019.04.004","article-title":"Pervasive H3K27 acetylation leads to ERV expression and a therapeutic vulnerability in H3K27M Gliomas","volume":"35","author":"Krug","year":"2019","journal-title":"Cancer Cell"},{"key":"R120-20250603","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ccell.2018.11.015","article-title":"Histone H3.3 K27M accelerates spontaneous brainstem glioma and drives restricted changes in bivalent gene expression","volume":"35","author":"Larson","year":"2019","journal-title":"Cancer Cell"},{"key":"R121-20250603","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/neuonc\/noab036","article-title":"Loss of H3K27me3 in meningiomas","volume":"23","author":"Nassiri","year":"2021","journal-title":"Neuro Oncol"},{"key":"R122-20250603","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00401-018-1844-9","article-title":"Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence","volume":"135","author":"Katz","year":"2018","journal-title":"Acta Neuropathol"},{"key":"R123-20250603","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"R124-20250603","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00401-004-0911-6","article-title":"DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q","volume":"108","author":"Bello","year":"2004","journal-title":"Acta Neuropathol"},{"key":"R125-20250603","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1750-3639.2009.00340.x","article-title":"Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas","volume":"20","author":"Barski","year":"2010","journal-title":"Brain Pathol"},{"key":"R126-20250603","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0165-4608(02)00799-9","article-title":"CpG island methylation of tumor-related genes in three primary central nervous system lymphomas in immunocompetent patients","volume":"142","author":"Gonzalez-Gomez","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"key":"R127-20250603","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature17157","article-title":"Deletions linked to TP53 loss drive cancer through p53-independent mechanisms","volume":"531","author":"Liu","year":"2016","journal-title":"Nature"},{"key":"R128-20250603","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3171\/JNS-07\/08\/0398","article-title":"Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A","volume":"107","author":"Nakane","year":"2007","journal-title":"J Neurosurg"},{"key":"R129-20250603","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0165-4608(03)00244-9","article-title":"Methylation status of TP73 in meningiomas","volume":"148","author":"Lomas","year":"2004","journal-title":"Cancer Genet Cytogenet"},{"key":"R130-20250603","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1158\/0008-5472.CAN-07-1796","article-title":"Specific genes expressed in association with progesterone receptors in meningioma","volume":"68","author":"Claus","year":"2008","journal-title":"Cancer Res"},{"key":"R131-20250603","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3171\/2017.2.JNS162566","article-title":"Prognostic value of estrogen receptor in WHO Grade III meningioma: a long-term follow-up study from a single institution","volume":"128","author":"Hua","year":"2018","journal-title":"J Neurosurg"},{"key":"R132-20250603","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clineuro.2014.06.015","article-title":"Is progesteron receptor status really a prognostic factor for intracranial meningiomas?","volume":"124","author":"Iplikcioglu","year":"2014","journal-title":"Clin Neurol Neurosurg"},{"key":"R133-20250603","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11060-009-0086-z","article-title":"Angiogenesis and expression of estrogen and progesterone receptors as predictive factors for recurrence of meningioma","volume":"98","author":"Guevara","year":"2010","journal-title":"J Neurooncol"},{"key":"R134-20250603","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.3171\/2013.10.FOCUS13341","article-title":"Recent developments in chemotherapy for meningiomas: a review","volume":"35","author":"Moazzam","year":"2013","journal-title":"Neurosurg Focus"},{"key":"R135-20250603","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01050266","article-title":"A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study","volume":"15","author":"Goodwin","year":"1993","journal-title":"J Neurooncol"},{"key":"R136-20250603","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1200\/JCO.2015.61.6490","article-title":"Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005","volume":"33","author":"Ji","year":"2015","journal-title":"J Clin Oncol"},{"key":"R137-20250603","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.4103\/jcrt.JCRT_1075_16","article-title":"Estrogen and progesterone receptor in meningiomas: an immunohistochemical analysis","volume":"16","author":"Telugu","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"R138-20250603","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3923\/pjbs.2012.530.535","article-title":"Status of Ki-67, estrogen and progesterone receptors in various subtypes of intracranial meningiomas","volume":"15","author":"Fakhrjou","year":"2012","journal-title":"Pak J Biol Sci"},{"key":"R139-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-006-9146-9","article-title":"Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression","volume":"80","author":"Korhonen","year":"2006","journal-title":"J Neurooncol"},{"key":"R140-20250603","doi-asserted-by":"crossref","first-page":"100111","DOI":"10.1016\/j.wnsx.2021.100111","article-title":"Expression of progesterone receptor and its association with clinicopathological characteristics in meningiomas: a cross-sectional study","volume":"12","author":"Mnango","year":"2021","journal-title":"World Neurosurg X"},{"key":"R141-20250603","doi-asserted-by":"crossref","first-page":"611218","DOI":"10.3389\/fonc.2021.611218","article-title":"Progesterone Receptor Expression in Meningiomas: Pathological and Prognostic Implications","volume":"11","author":"Maiuri","year":"2021","journal-title":"Front Oncol"},{"key":"R142-20250603","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/jcp.2004.018333","article-title":"The prognostic value of progesterone receptor status in meningiomas","volume":"57","author":"Roser","year":"2004","journal-title":"J Clin Pathol"},{"key":"R143-20250603","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3171\/jns.2006.105.2.163","article-title":"Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas","volume":"105","author":"Pravdenkova","year":"2006","journal-title":"J Neurosurg"},{"key":"R144-20250603","first-page":"13185","article-title":"Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance","volume":"8","author":"Silva","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"R145-20250603","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1007\/s10143-021-01651-w","article-title":"The immunohistochemical expression of SSTR2A is an independent prognostic factor in meningioma","volume":"45","author":"Fodi","year":"2022","journal-title":"Neurosurg Rev"},{"key":"R146-20250603","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2967\/jnumed.114.149120","article-title":"Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue","volume":"56","author":"Rachinger","year":"2015","journal-title":"J Nucl Med"},{"key":"R147-20250603","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/neuonc\/now001","article-title":"68Gallium-DOTATATE PET in meningioma: a reliable predictor of tumor growth rate","volume":"18","author":"Sommerauer","year":"2016","journal-title":"Neuro Oncol"},{"key":"R148-20250603","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jon.12632","article-title":"Gallium-68 DOTATATE PET in the evaluation of intracranial meningiomas","volume":"29","author":"Ivanidze","year":"2019","journal-title":"J Neuroimaging"},{"key":"R149-20250603","first-page":"1053","article-title":"PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas","volume":"42","author":"Henze","year":"2001","journal-title":"J Nucl Med"},{"key":"R150-20250603","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13014-017-0913-x","article-title":"First intraindividual comparison of contrast-enhanced MRI, FET- and DOTATOC- PET in patients with intracranial meningiomas","volume":"12","author":"Dittmar","year":"2017","journal-title":"Radiat Oncol"},{"key":"R151-20250603","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.2967\/jnumed.117.191932","article-title":"Improved detection of transosseous meningiomas using 68Ga-DOTATATE PET\/CT compared with contrast-enhanced MRI","volume":"58","author":"Kunz","year":"2017","journal-title":"J Nucl Med"},{"key":"R152-20250603","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1748-717X-4-56","article-title":"[68Ga]-DOTATOC-PET\/CT for meningioma IMRT treatment planning","volume":"4","author":"Gehler","year":"2009","journal-title":"Radiat Oncol"},{"key":"R153-20250603","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00259-012-2155-3","article-title":"Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET\/CT and contrast-enhanced MRI","volume":"39","author":"Afshar-Oromieh","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R154-20250603","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.3171\/2019.3.FOCUS1925","article-title":"Impact of 68Ga-DOTATOC PET\/MRI on robotic radiosurgery treatment planning in meningioma patients: first experiences in a single institution","volume":"46","author":"Acker","year":"2019","journal-title":"Neurosurg Focus"},{"key":"R155-20250603","first-page":"1913","article-title":"Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma","volume":"39","author":"Klutmann","year":"1998","journal-title":"J Nucl Med"},{"key":"R156-20250603","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF01476412","article-title":"High sensitivity of the in vivo detection of somatostatin receptors by 111indium (DTPA-octreotide)-scintigraphy in meningioma patients","volume":"126","author":"Hildebrandt","year":"1994","journal-title":"Acta Neurochir (Wien)"},{"key":"R157-20250603","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/00006231-199604000-00157","article-title":"Somatostatin receptor scintigraphy in the differential diagnosis of meningioma","volume":"17","author":"Bohuslavizki","year":"1996","journal-title":"Nucl Med Commun"},{"key":"R158-20250603","first-page":"102","article-title":"Clinical relevance of somatostatin receptor scintigraphy in patients with skull base tumours","volume":"65","author":"Luyken","year":"1996","journal-title":"Acta Neurochir Suppl"},{"key":"R159-20250603","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/00006231-199509000-00006","article-title":"Somatostatin receptor imaging in CNS tumours using 111In-octreotide","volume":"16","author":"Maini","year":"1995","journal-title":"Nucl Med Commun"},{"key":"R160-20250603","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11060-006-9210-5","article-title":"The role of 111indium-octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas","volume":"81","author":"Nathoo","year":"2007","journal-title":"J Neurooncol"},{"key":"R161-20250603","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11060-013-1146-y","article-title":"Correlation between 99mTc-HYNIC-octreotide SPECT\/CT somatostatin receptor scintigraphy and pathological grading of meningioma","volume":"113","author":"Wang","year":"2013","journal-title":"J Neurooncol"},{"key":"R162-20250603","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3389\/fonc.2020.01633","article-title":"Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"key":"R163-20250603","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/neuonc\/nor044","article-title":"Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma","volume":"13","author":"Johnson","year":"2011","journal-title":"Neuro Oncol"},{"key":"R164-20250603","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.3171\/2011.1.FOCUS111","article-title":"Treatment of unresectable skull base meningiomas with somatostatin analogs","volume":"30","author":"Schulz","year":"2011","journal-title":"Neurosurg Focus"},{"key":"R165-20250603","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1212\/WNL.0000000000001153","article-title":"Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma","volume":"84","author":"Norden","year":"2015","journal-title":"Neurology"},{"key":"R166-20250603","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2967\/jnumed.114.147256","article-title":"Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial","volume":"56","author":"Marincek","year":"2015","journal-title":"J Nucl Med"},{"key":"R167-20250603","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.molcel.2021.05.029","article-title":"Oncogenic signaling of RTK fusions becomes more granular","volume":"81","author":"Cuneo","year":"2021","journal-title":"Mol Cell"},{"key":"R168-20250603","doi-asserted-by":"crossref","first-page":"11659","DOI":"10.3390\/ijms222111659","article-title":"Emerging importance of tyrosine kinase inhibitors against cancer: quo vadis to cure","volume":"22","author":"Mongre","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R169-20250603","first-page":"139","article-title":"Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: an immunohistochemical and fluorescence in situ hybridization pilot study","volume":"57","author":"Caltabiano","year":"2013","journal-title":"J Neurosurg Sci"},{"key":"R170-20250603","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jocn.2013.06.008","article-title":"An audit of immunohistochemical marker patterns in meningioma","volume":"21","author":"Baxter","year":"2014","journal-title":"J Clin Neurosci"},{"key":"R171-20250603","doi-asserted-by":"crossref","first-page":"e37204","DOI":"10.1371\/journal.pone.0037204","article-title":"EGFR soluble isoforms and their transcripts are expressed in meningiomas","volume":"7","author":"Guillaudeau","year":"2012","journal-title":"PLoS One"},{"key":"R172-20250603","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-009-9948-7","article-title":"Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma","volume":"96","author":"Norden","year":"2010","journal-title":"J Neurooncol"},{"key":"R173-20250603","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s11060-018-2922-5","article-title":"Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2","volume":"139","author":"Osorio","year":"2018","journal-title":"J Neurooncol"},{"key":"R174-20250603","first-page":"938","article-title":"Vascular endothelial growth factor, hepatocyte growth factor\/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy","volume":"46","author":"Lamszus","year":"2000","journal-title":"Neurosurgery"},{"key":"R175-20250603","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10014-018-0332-1","article-title":"The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival","volume":"36","author":"Nakada","year":"2019","journal-title":"Brain Tumor Pathol"},{"key":"R176-20250603","first-page":"1157","article-title":"Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas","volume":"28","author":"Baumgarten","year":"2013","journal-title":"Histol Histopathol"},{"key":"R177-20250603","doi-asserted-by":"crossref","first-page":"352","DOI":"10.5414\/NP300488","article-title":"Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches","volume":"31","author":"Preusser","year":"2012","journal-title":"Clin Neuropathol"},{"key":"R178-20250603","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11060-005-9078-9","article-title":"Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors","volume":"82","author":"Maiuri","year":"2007","journal-title":"J Neurooncol"},{"key":"R179-20250603","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol"},{"key":"R180-20250603","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"R181-20250603","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(17)30843-4","article-title":"Bevacizumab in adjuvant treatment of non-small-cell lung cancer","volume":"18","author":"Weiss","year":"2017","journal-title":"Lancet Oncol"},{"key":"R182-20250603","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1200\/JCO.2017.76.0611","article-title":"Phase II, open-label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma","volume":"36","author":"Grill","year":"2018","journal-title":"J Clin Oncol"},{"key":"R183-20250603","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S1470-2045(16)00011-5","article-title":"Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study","volume":"17","author":"Bertucci","year":"2016","journal-title":"Lancet Oncol"},{"key":"R184-20250603","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11060-012-0861-0","article-title":"Bevacizumab therapy for adults with recurrent\/progressive meningioma: a retrospective series","volume":"109","author":"Lou","year":"2012","journal-title":"J Neurooncol"},{"key":"R185-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02478918","article-title":"Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression","volume":"18","author":"Nagashima","year":"2001","journal-title":"Brain Tumor Pathol"},{"key":"R186-20250603","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3171\/jns.2001.94.2.0293","article-title":"Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells","volume":"94","author":"Johnson","year":"2001","journal-title":"J Neurosurg"},{"key":"R187-20250603","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1215\/15228517-2009-010","article-title":"Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)","volume":"11","author":"Wen","year":"2009","journal-title":"Neuro Oncol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T15:01:40Z","timestamp":1748962900000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,20]]},"references-count":183,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000002391","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,20]]}}}